Y15

CAS No. 4506-66-5

Y15( 1245-Benzenetetramine tetrahydrochlor | FAK inhibitor Y15 | FAK Inhibitor 14 )

Catalog No. M20681 CAS No. 4506-66-5

Y15 is a potent and specificsmall-molecule FAK scaffolding inhibitor that inhibits its autophosphorylation activity blocks tumor growth.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 39 In Stock
50MG 68 In Stock
100MG 125 In Stock
200MG 178 In Stock
500MG 314 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Y15
  • Note
    Research use only, not for human use.
  • Brief Description
    Y15 is a potent and specificsmall-molecule FAK scaffolding inhibitor that inhibits its autophosphorylation activity blocks tumor growth.
  • Description
    Y15 is a potent and specificsmall-molecule FAK scaffolding inhibitor that inhibits its autophosphorylation activity blocks tumor growth.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    1245-Benzenetetramine tetrahydrochlor | FAK inhibitor Y15 | FAK Inhibitor 14
  • Pathway
    Angiogenesis
  • Target
    FAK
  • Recptor
    FAK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    4506-66-5
  • Formula Weight
    284.01
  • Molecular Formula
    C6H14Cl4N4
  • Purity
    >98% (HPLC)
  • Solubility
    H2O:59 mg/mL (207.74 mM; Need ultrasonic and warming)
  • SMILES
    Cl.Cl.Cl.Cl.Nc1cc(N)c(N)cc1N
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.O'Brien S Golubovskaya VM Conroy Jet al.FAK inhibition with small molecule inhibitor Y15 decreases viability clonogenicity and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics[J].Oncotarget. 2014 Sep 15;5(17):7945-59.
molnova catalog
related products
  • AMP-945

    AMP-945 is a proprietary focal adhesion kinase (FAK) inhibitor.

  • Tasimelteon

    Tasimelteon is a melatonin receptor agonist that is used for the treatment of non-24 hour sleep-wake disorder in blind individuals.

  • NAMI-A

    NAMI-A, a ruthenium-based compound, selectively targets tumor metastasis by inhibiting cancer cell adhesion and migration.